Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

The efficacy of Li in bipolar disorder

Authors Lozano R, Marín R, Santacruz MJ, Freire I, Gomez R

Received 16 May 2013

Accepted for publication 17 May 2013

Published 11 July 2013 Volume 2013:9 Pages 953—954


R Lozano,1 R Marín,2 MJ Santacruz,2 I Freire,2 R Gomez2

1Department of Pharmacy, 2Department of Psychiatry, Hospital Real Nuestra Señora de Gracia, Zaragoza, Spain

The efficacy of lithium (Li) for acute mania and as prophylaxis against recurrent episodes of mania in bipolar disorder has been well established, with the minimum effective Li serum concentration for acute mania in the range of 0.6–1.2 mEq/L, although lower maintenance concentrations can prove effective in some patients.1–5
Thyroid disorders are also associated with alterations in mood, and patients with hypothyroidism may present with depression and cognitive dysfunction,6–8 while patients with hyperthyroidism may present with anxiety, depression, mood lability,7,9 and manic symptoms.10 However, considering that overt hyperthyroidism is uncommon in bipolar disorder, with a prevalence ≤2% across different studies,11,12 this has been largely attributed to lithium,13 with rates varying from 0 to 47% (average of about 10%) among patients on long-term treatment with lithium.13–16

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Influence of hypothyroidism on renal function of lithium-treated patients

Lozano R, Marín R, Santacruz MJ

Neuropsychiatric Disease and Treatment 2016, 12:25-27

Published Date: 23 December 2015

Analysis of the cumulative effect of schizophrenia-related single nucleotide polymorphisms

Lozano R, Marín R, Freire I, Santacruz MJ, Pascual-García A

Neuropsychiatric Disease and Treatment 2014, 10:1079-1080

Published Date: 12 June 2014

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model

Lozano R, Domeque N, Apesteguia AF

Clinical Pharmacology: Advances and Applications 2013, 5:153-159

Published Date: 27 September 2013

Reducing serum cholesterol levels in women

Lozano R

Neuropsychiatric Disease and Treatment 2012, 8:405-406

Published Date: 12 September 2012

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010